Bifogade filer
PDF
Kurs & Likviditet
Beskrivning
| Land | Danmark |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Hørsholm, Denmark, May 11, 2021 - ExpreS2ion Biotech Holding AB's affiliate ExpreS2ion Biotechnologies ApS ("ExpreS2ion") announces the selection of its lead candidate HER2-cVLP breast cancer vaccine. The project runs according to plan.
ExpreS[2]ion, with the expert assistance of Prof. Pier Luigi Lollini at the Interdepartmental Center for Cancer Research, University of Bologna, has started the preclinical program, exploiting state-of-the-art in vitro and in vivo models mimicking some of the mechanisms in human breast cancer.
As part of the preclinical program, ExpreS[2]ion has selected the lead candidate, ES2B-C001, from a pool of several optimized constructs. The lead candidate - even without adjuvant - has been found to induce high anti-HER2 antibody titres when compared to a former construct earlier published in OncoImmunology, 2018 (https://www.tandfonline.com/doi/full/10.1080/2162402X.2017.1408749).
The ES2B-C001 breast cancer vaccine programme continues to be on path towards expected preclinical proof of concept data at the end of 2021, as well as starting the clinical program in 2022 with GMP manufacturing of ES2B-C001 with the plan to start a clinical Phase I safety and immune response study in beginning of 2023.
CEO Bent U. Frandsen comments
"Following the recent in-licensing of the HER2-cVLP breast cancer vaccine project from AdaptVac, as well as the initiation of the preclinical work in collaboration with Prof. Lollini at University of Bologna, it now becomes very tangible following the selection of the lead vaccine candidate. I am pleased that we are on track on this exciting project."
Certified Adviser
Svensk Kapitalmarknadsgranskning AB
Telefon: +46 11 32 30 732
E-post: ca@skmg.se
This press release constitutes inside information that ExpreS2ion Biotech Holding AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation 596/2014. The information was sent for publication, through the agency of the contact persons set out above, at the time stated by the Company's news distributor, Cision, at the publication of this press release.